Ranbaxy gets US nod for cholesterol reducing generic drug

Tuesday, 01 June 2004, 19:30 IST
Printer Print Email Email
NEW DELHI: Indian pharmaceutical major Ranbaxy Laboratories Limited (RLL) has received tentative approval from the US Food and Drug Administration (FDA) for its cholesterol reducing generic drug. Considered equivalent to Abbott Laboratories' Tericor, Ranbaxy has been given permission to manufacture and market its Fenofibrate tablets in dosages of 54 mg, 107 mg and 160 mg, the company stated Monday. The total market sales for Tericor were $669 million in a total Fenofibrate market of $675 million in the last fiscal ended March 31. Fenofibrate is indicated for the treatment of hypercholesterolemia or as adjunctive therapy to diet to reduce cholesterol. "Subject to receiving final FDA approval, we will introduce Fenofibrate tablets to further expand our product portfolio of affordable generic alternatives," said Jim Meehan, vice president of sales and marketing of Florida based Ranbaxy Pharmaceuticals Incorporated (RPI).
Source: IANS
siliconindia